Vancomycin-Resistant Enterococcus Ventriculitis in a Child

Year 2014, Volume: 11 Issue: 1, - , 01.03.2014

Nejmi Kıymaz Burhan Oral Büdü Metehan Eseoğlu İsmail Demir

https://doi.org/10.15197/sabad.1.11.12

Abstract

One of the most frequently encountered problems associated with ventriculoperitoneal (VP) shunts which are used in the treatment of hydrocephaly is infection. Staphylococcus is considered the most prominent factor in VP shunt infections; Enterococcus is less likely to cause ventriculitis in such patients. A shunt ventriculitis was demonstrated in a 1.5-year-old boy. The VP shunts was removed and an external ventricular drainage system was inserted. Subsequently empiric vancomycin and cephotaxime treatment was started. Vancomycin-resistant Enterococcus faecium (VREF) began to proliferate in the cerebrospinal fluid culture, and therefore we initiated linezolid and imipenem therapy by the intravenous route. The patient underwent a VP shunt operation 45 days after. In this study, successful therapy with linezolid in VP shunt ventriculitis due to VREF is presented.

Keywords

Child, ventriculitis, linezolid

Vancomycin-Resistant Enterococcus Ventriculitis in a Child

Abstract

Hidrosefalinin tedavisinde yaygın olarak kullanılan ventrikülo-peritoneal (VP) şantlarda, karşılaşılan zorlukların başında şant effeksiyonları gelmektedir. VP şant enfeksiyonuna bağlı ventrikülit tespit ettiğimiz 1,5 yaşındaki erkek hastada VP şantı çıkarıp, eksternal ventriküler drenaja aldık. Ampirik olarak vankomisin ve sefotaksim tedavisi başlandı. Beyin omurilik sıvısı kültüründe vankomisine rezistans enterobakter facium üremesi üzerine intravenöz linezolid ve imipenam tedavisi başlandı. 45 gün sonra hastaya tekrar VP şant takıldı. Bu çalışmada vankomisine rezistans enterokok ventrikülitinin linezolid ile başarılı tedavisini sunduk

Keywords

Çocuk, ventrikülit, linezolid

References

• Zemack G, Romner B. Seven years of clinical experience withthe programmable Codman Hakim valve: a retrospec- tive study of 583 patients. J Neurosurg 2000;92:941-8.
• Choux M, Gentori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg 1992;77:875-80.
• Bremer AA, Darouiche RO. Ventriculoperitoneal shunt in- fection due to Serratia marcescens. J Infect 2005;50:138– 41.
• Enger PO, Svendsen F, Wester K. CSF shunt infections in children: experiences from a population-based study. Acta Neurochir 2003;145:243-8.
• Stevenson KB, Murray EW, Sarubbi FA. Enterococcal men- ingitis: report of four cases and review. Clin Infect Dis 1994;18:233–9.
• Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002;21:798-800.
• Lucas da Silva PS, Neto HM, Sejas LM. Successful Treatment of Vancomycin-Resistant Enterococcus Ventriculitis in a Child BJID 2007;11:297-9.
• Maranich AM, Rajnik M. Successful treatment of vanco- mycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med 2008;173:927-9.
• Pelz RK, Lipsett PA, Swoboda SM. Vancomycinsensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002;28:692–7.
• Kestle JR, Garton HJ, Whitehead WE, et al. Management of shunt infections: a multicenter pilot study. J Neurosurg 2006;105:177-81.
• Gold HS: Vancomycin-resistant enterococci. mechanisms and clinical observations. Clin Infect Dis 2001;33:210–9. 51
• Saiman L, Goldfarb J, Kaplan SA. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;22:193- 200.
• Meissner HC, Townsend T, Wenman W. Hematologic ef- fects of linezolid in young children. Pediatr Infect Dis J 2003;22:186-92.